Webcast

Cutting Through Comorbidities: Clearing the Way to Appropriate Anticoagulant Therapy in Patients at Risk for Deep Vein Thrombosis and Pulmonary Embolism

Launch Date
06/22/2021
Credit Amount
0.00 Expired
Credit Expires
06/22/2022

Faculty

Gregory Piazza, MD, MS
Director, Vascular Medicine Section, Brigham and Women's Hospital
Associate Professor of Medicine, Cardiovascular Medicine, Harvard Medical School, Boston, MA
Gregory Piazza, MD, MS
Director, Vascular Medicine Section, Brigham and Women's Hospital

Dr. Piazza is an Associate Professor of Medicine at Harvard Medical School, and serves as faculty in the Cardiovascular Division at Brigham and Women’s Hospital. Dr. Piazza received his medical degree from the University of Massachusetts Medical School in Worcester, Massachusetts, and completed a residency in internal medicine, general cardiology fellowship, an advanced cardiovascular imaging fellowship, and served as chief medical resident at Beth Israel Deaconess Medical Center in Boston. He also completed a National Heart Lung and Blood Institute- sponsored advanced fellowship in vascular medicine at Brigham and Women’s Hospital. Dr. Piazza’s research interests include the epidemiology, pathophysiology, diagnosis, treatment, and prevention of venous thromboembolism, thrombophilia-associated infertility, computerized decision support to improve cardiovascular outcomes, as well as stroke prevention in atrial fibrillation.

Geoffrey Barnes, MD, MSc
Assistant Professor, Cardiovascular Medicine and Vascular Medicine
Department of Internal Medicine, Division of Cardiovascular Medicine, University of Michigan Health System, Ann Arbor, MI
Geoffrey Barnes, MD, MSc
Assistant Professor, Cardiovascular Medicine and Vascular Medicine

Dr. Barnes is a cardiologist and vascular medicine specialist at the University of Michigan Health System. His clinical and research interests center around the care of patients with thrombotic conditions and/or who require the use of anticoagulant medications. He is also a health services researcher with expertise in implementation science. He serves as co-director for the Michigan Anticoagulation Quality Improvement Initiative (MAQI2) and is currently funded by NHLBI and AHRQ to improve the delivery of anticoagulation care. He serves in leadership roles with numerous organizations, including the Anticoagulation Forum, American College of Cardiology, and American Heart Association.

Explore By Section
Statement of Need Learning Objectives Financial Support Target Audience Credit Information Disclosure Declaration Obtaining Credit

Statement of Need

Venous thromboembolism (VTE) comprises deep vein thrombosis (DVT) and pulmonary embolism (PE) and affects up to 900,000 individuals in the U.S. each year, leading to nearly 100,000 annual VTE-related deaths. While it is the most preventable cause of death in hospitalized patients, its incidence will continue to rise with the aging population and as people live longer with chronic conditions.

In this CME Outfitters BriefCase you will meet Walter, a 71-year-old African-American male who presents to his primary care physician’s office with swelling in his right leg. Expert faculty will assess the common comorbidities and discuss applying anticoagulant strategies that reflect randomized controlled trials (RCTs), real-world data, and individual patient characteristics.

Learning Objectives

At the end of this CME/CE activity, participants should be able to:

  • Assess common comorbidities in patients requiring anticoagulants.
  • Apply anticoagulant strategies to the care of patients that reflect RCTs, real-world data, and individual patient characteristics.

The following learning objectives pertain only to those requesting CNE or CPE credit:

  • Identify common comorbidities in patients requiring anticoagulants.
  • Summarize anticoagulant strategies for the care of patients that reflect RCTs, real-world data, and individual patient characteristics.

Financial Support

Supported by educational grants from the Bristol Myers Squibb and Pfizer Alliance and Janssen Pharmaceuticals, Inc. administered by Janssen Scientific Affairs, LLC.

Target Audience

VTE specialists, pulmonologists, hematologist-oncologists, emergency physicians, internists, family practitioners, PAs, nurse practitioners, and pharmacists.

Credit Information

Physicians (ACCME) 1.0

CME Outfitters, LLC, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Pharmacists/Pharmacy Tech (ACPE) 1.0

This application-based activity is approved for 1.0 contact hour (0.10 CEUs) of continuing pharmacy credit.
Activity UAN: 0376-0000-21-062-H02-P

ABIM MOC 1.0

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 medical knowledge MOC point in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Royal College MOC

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

MIPS Improvement Activity

Completion of this accredited CME activity meets the expectations of an Accredited Safety or Quality Improvement Program (IA_PSPA_28) for the Merit-based Incentive Payment Program (MIPS). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.

Note to Nurse Practitioners

Nurse Practitioners can apply for AMA PRA Category 1 Credit ™ through the American Academy of Nurse Practitioners (AANP). AANP will accept AMA PRA Category 1 Credit ™ from organizations accredited by the Accreditation Council for Continuing Medical Education. Nurse practitioners can also apply for credit through their state boards.

Disclosure Declaration

It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.

Dr. Piazza reports that he receives grants from Amgen Inc.; Bayer; Bristol Myers Squibb and Pfizer Alliance; Boston Scientific Corporation; Janssen Pharmaceuticals, Inc.; and Portola Pharmaceuticals, Inc.

Dr. Barnes reports that he receives grants from Agency for Healthcare Research and Quality (AHRQ); Blue Cross Blue Shield of Michigan and National Heart, Lung, and Blood Institute (NHLBI). He is a consultant for Acelis Connected Health; AMAG Pharmaceuticals; Bristol Myers Squibb and Pfizer Alliance and Janssen Pharmaceuticals, Inc. He receives other financial or material support as a member of the Board of Directors – Anticoagulation Forum and National Certification Board of Anticoagulation Providers.

  • Warren Beckman (planning committee) has no disclosures to report.
  • Maria Glukhovsky, PharmD (planning committee) has no disclosures to report.
  • Jan Perez (planning committee) has no disclosures to report.
  • Sharon Tordoff (planning committee) has no disclosures to report.
  • Disclosures were obtained from the CME Outfitters, LLC staff: No disclosures to report.

Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.

Obtaining Credit

Post-tests, credit request forms, and activity evaluations must be completed online (requires free account activation), and participants can print their certificate or statement of credit immediately (75% pass rate required). This website supports all browsers except Internet Explorer for Mac. For complete technical requirements and privacy policy, visit our Privacy & Confidentiality page.

 

NOTE: Pharmacist CE Universal Activity Number, Enduring: 0376-0000-21-062-H02-P.

Questions about this activity?

Call us at 877.CME.PROS (877.263.7767).

BC-046-062221-90

Cutting Through Comorbidities: Clearing the Way to Appropriate Anticoagulant Therapy in Patients at Risk for Deep Vein Thrombosis and Pulmonary Embolism
Event Date: 06/22/2021